Patents by Inventor Yiliang Li
Yiliang Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11948732Abstract: A compression-molding method for a permanent includes: providing a drive coil to generate an electromagnetic force when a transient current is passed into the drive coil, so as to apply a molding compression force to magnetic powder under compression, and providing an orientation coil to generate an orientation magnetic field when a transient current is passed into the orientation coil, thereby providing the magnetic powder under compression with an anisotropic property; and synchronously passing the transient currents to the drive coil and the orientation coil to synchronously generate the electromagnetic force and the orientation magnetic field, thereby completing compression-molding of the permanent magnet, wherein a magnitude of the electromagnetic force and an intensity of the orientation magnetic field are respectively changed by changing peak values of the transient currents.Type: GrantFiled: July 12, 2023Date of Patent: April 2, 2024Assignee: HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: Liang Li, Yiliang Lv
-
GPS Interference Source Positioning Method, Apparatus, Electronic Device, and Readable Storage Media
Publication number: 20240094406Abstract: The present invention provides a GPS interference source positioning method, apparatus, electronic device, and readable storage medium, which relates to the technical field of wireless communications.Type: ApplicationFiled: June 13, 2023Publication date: March 21, 2024Inventors: Zhiyong FENG, Sai HUANG, Jingchun LI, Yiliang CHEN, Ping ZHANG, Shuo CHANG -
Publication number: 20240083994Abstract: Provided are a cell strain for producing a biosimilar drug of Ustekinumab and a production method therefor. Specifically, provided is a Chinese hamster ovary cell S cell strain. The cell strain expresses a full human monoclonal antibody directed against the P40 subunit shared by human IL-12 and human IL-23. The fully human monoclonal antibody directed against the P40 subunit shared by human IL-12 and human IL-23 is a biosimilar drug of Ustekinumab, which not only exhibits high consistency with Ustekinumab in pre-clinical research, but also passes pharmacokinetic bioequivalence and safety similarity evaluation in clinical research. The biosimilar drug of Ustekinumab is the first one that has entered clinical trials in China, is the only one that has completed the I stage clinical trial, and is also one of the biosimilar drugs of Ustekinumab, which has the fastest progress in new drug application in the world.Type: ApplicationFiled: March 23, 2021Publication date: March 14, 2024Applicant: QYUNS THERAPEUTICS CO., LTD.Inventors: Zhengxue XU, Tao LI, Yin CHEN, Wenjun HUANG, Yi WANG, Huaiyao QIAO, Min FANG, Yiliang WU, Mengdan ZHANG
-
Publication number: 20230129381Abstract: Embodiments of the instant disclosure relate to novel methods and compositions for treating tumors resistant to one or more anticancer drugs, such as platinum-based chemotherapeutics.Type: ApplicationFiled: September 14, 2022Publication date: April 27, 2023Inventors: WENGE ZHU, JING LI, YILIANG LI
-
Publication number: 20230012172Abstract: Embodiments of the instant disclosure relate to novel methods and compositions for treating tumors resistant to platinum-based chemotherapy. In certain embodiments, methods of treating tumors herein can include administering an effective amount of at least one ursolic acid derivative. In certain embodiments, methods of treating tumors herein can include administering an effective amount of at least one ursolic acid derivative in combination with at least one platinum-based chemotherapeutic separately or in a combination therapy. In some embodiments, methods of treating tumors disclosed herein can include screening and/or selecting a subject suitable for treatment on the basis of SENP1 tumor expression. In other embodiments, methods of treating tumors can include administering a composition disclosed herein to a subject, the composition having a combination of at least one ursolic acid derivative and at least one platinum-based chemotherapeutic.Type: ApplicationFiled: August 22, 2022Publication date: January 12, 2023Inventors: Wenge ZHU, Jing LI, Ruiqin WU, Yiliang LI
-
Patent number: 10626022Abstract: An integrated apparatus for chemical precipitation and rapid filtration of water samples. The invention relates to an apparatus for chemical precipitation and filtration of water samples. The integrated apparatus includes a reaction vessel, a lid of reaction vessel, a opening for reagent addition and gas leakage, an aerating tube, a support, a liquid phase remover, a solid phase collector, a control cover of the liquid phase remover, and a control cover of the solid phase collector.Type: GrantFiled: April 1, 2016Date of Patent: April 21, 2020Assignee: Third Institute of Oceanography, State Oceanic AdministrationInventors: Jianhua He, Yiliang Li, Dekun Huang, Feng Lin, Wu Men, Wen Yu, Fangfang Deng, Jing Lin, Fenfen Wang, Jialin Ni, Tao Yu
-
Publication number: 20180362363Abstract: An integrated apparatus for chemical precipitation and rapid filtration of water samples. The invention relates to an apparatus for chemical precipitation and filtration of water samples. The integrated apparatus includes a reaction vessel, a lid of reaction vessel, a opening for reagent addition and gas leakage, an aerating tube, a support, a liquid phase remover, a solid phase collector, a control cover of the liquid phase remover, and a control cover of the solid phase collector.Type: ApplicationFiled: April 1, 2016Publication date: December 20, 2018Applicant: Third Institute of Oceanography, State Oceanic AdministrationInventors: Jianhua He, Yiliang Li, Dekun Huang, Feng Lin, Wu Men, Wen Yu, Fangfang Deng, Jing Lin, Fenfen Wang, Jialin Ni, Tao Yu
-
Patent number: 9768333Abstract: The invention is directed to a method for producing non-oxide semiconductor nanoparticles, the method comprising: (a) subjecting a combination of reaction components to conditions conducive to microbially-mediated formation of non-oxide semiconductor nanoparticles, wherein said combination of reaction components comprises i) anaerobic microbes, ii) a culture medium suitable for sustaining said anaerobic microbes, iii) a metal component comprising at least one type of metal ion, iv) a non-metal component comprising at least one non-metal selected from the group consisting of S, Se, Te, and As, and v) one or more electron donors that provide donatable electrons to said anaerobic microbes during consumption of the electron donor by said anaerobic microbes; and (b) isolating said non-oxide semiconductor nanoparticles, which contain at least one of said metal ions and at least one of said non-metals.Type: GrantFiled: April 7, 2014Date of Patent: September 19, 2017Assignees: UT-BATTELLE, LLC, UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventors: Tommy J. Phelps, Robert J. Lauf, Ji-Won Moon, Adam Justin Rondinone, Lonnie J. Love, Chad Edward Duty, Andrew Stephen Madden, Yiliang Li, Ilia N. Ivanov, Claudia Jeanette Rawn
-
Publication number: 20140220654Abstract: The invention is directed to a method for producing non-oxide semiconductor nanoparticles, the method comprising: (a) subjecting a combination of reaction components to conditions conducive to microbially-mediated formation of non-oxide semiconductor nanoparticles, wherein said combination of reaction components comprises i) anaerobic microbes, ii) a culture medium suitable for sustaining said anaerobic microbes, iii) a metal component comprising at least one type of metal ion, iv) a non-metal component comprising at least one non-metal selected from the group consisting of S, Se, Te, and As, and v) one or more electron donors that provide donatable electrons to said anaerobic microbes during consumption of the electron donor by said anaerobic microbes; and (b) isolating said non-oxide semiconductor nanoparticles, which contain at least one of said metal ions and at least one of said non-metals.Type: ApplicationFiled: April 7, 2014Publication date: August 7, 2014Inventors: Tommy J. Phelps, Robert J. Lauf, Ji-Won Moon, Adam Justin Rondinone, Lonnie J. Love, Chad Edward Duty, Andrew Stephen Madden, Yiliang Li, Ilia N. Ivanov, Claudia Jeanette Rawn
-
Patent number: 8759053Abstract: The invention is directed to a method for producing non-oxide semiconductor nanoparticles, the method comprising: (a) subjecting a combination of reaction components to conditions conducive to microbially-mediated formation of non-oxide semiconductor nanoparticles, wherein said combination of reaction components comprises i) anaerobic microbes, ii) a culture medium suitable for sustaining said anaerobic microbes, iii) a metal component comprising at least one type of metal ion, iv) a non-metal component containing at least one non-metal selected from the group consisting of S, Se, Te, and As, and v) one or more electron donors that provide donatable electrons to said anaerobic microbes during consumption of the electron donor by said anaerobic microbes; and (b) isolating said non-oxide semiconductor nanoparticles, which contain at least one of said metal ions and at least one of said non-metals.Type: GrantFiled: February 3, 2009Date of Patent: June 24, 2014Assignees: UT-Battelle, LLC, University of Tennessee Research FoundationInventors: Tommy J. Phelps, Robert J. Lauf, Ji Won Moon, Adam J. Rondinone, Lonnie J. Love, Chad Edward Duty, Andrew Stephen Madden, Yiliang Li, Ilia N. Ivanov, Claudia Jeanette Rawn
-
Patent number: 8481577Abstract: The present invention relates to the field of drugs associated with treating diabetes. Particularly, the present invention relates to a dipeptidyl peptidase-IV inhibitor having the structure shown by formula (I), which contains amide thiazole structure and has an effect on treating diabetes, and a preparation method and a pharmaceutical composition containing it, as well as use thereof in manufacture of the drugs for treating the diabetes, wherein, R1 is methyl; R2 is phenyl; phenyl, 2-thienyl substituted in a mono-substituted, bi-substituted manner by fluorine and methyl.Type: GrantFiled: June 16, 2011Date of Patent: July 9, 2013Assignee: Tianjin Institute of Pharmaceutical ResearchInventors: Guilong Zhao, Weiren Xu, Yuli Wang, Lida Tang, Yiliang Li, Meixiang Zou, Wei Liu, Hua Shao, Chubing Tan, Peng Liu
-
Publication number: 20110281922Abstract: The present invention relates to the field of drugs associated with treating diabetes. Particularly, the present invention relates to a dipeptidyl peptidase-IV inhibitor having the structure shown by formula (I), which contains amide thiazole structure and has an effect on treating diabetes, and a preparation method and a pharmaceutical composition containing it, as well as use thereof in manufacture of the drugs for treating the diabetes, wherein, R1 is methyl; R2 is phenyl; phenyl, 2-thienyl substituted in a mono-substituted, bi-substituted manner by fluorine and methyl.Type: ApplicationFiled: June 16, 2011Publication date: November 17, 2011Applicant: TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCHInventors: Guilong ZHAO, Weiren Xu, Yuli Wang, Lida Tang, Yiliang Li, Meixiang Zou, Wei Liu, Hua Shao, Chubing Tan, Peng Liu
-
Publication number: 20100330367Abstract: The invention is directed to a method for producing non-oxide semiconductor nanoparticles, the method comprising: (a) subjecting a combination of reaction components to conditions conducive to microbially-mediated formation of non-oxide semiconductor nanoparticles, wherein said combination of reaction components comprises i) anaerobic microbes, ii) a culture medium suitable for sustaining said anaerobic microbes, iii) a metal component comprising at least one type of metal ion, iv) a non-metal component comprising at least one non-metal selected from the group consisting of S, Se, Te, and As, and v) one or more electron donors that provide donatable electrons to said anaerobic microbes during consumption of the electron donor by said anaerobic microbes; and (b) isolating said non-oxide semiconductor nanoparticles, which contain at least one of said metal ions and at least one of said non-metals.Type: ApplicationFiled: September 2, 2010Publication date: December 30, 2010Applicant: UT-BATTELLE, LLCInventors: Tommy J. Phelps, Robert J. Lauf, Ji Won Moon, Adam J. Rondinone, Lonnie J. Love, Chad Edward Duty, Andrew Stephen Madden, Yiliang Li, Ilia N. Ivanov, Claudia Jeanette Rawn
-
Publication number: 20100193752Abstract: The invention is directed to a method for producing non-oxide semiconductor nanoparticles, the method comprising: (a) subjecting a combination of reaction components to conditions conducive to microbially-mediated formation of non-oxide semiconductor nanoparticles, wherein said combination of reaction components comprises i) anaerobic microbes, ii) a culture medium suitable for sustaining said anaerobic microbes, iii) a metal component comprising at least one type of metal ion, iv) a non-metal component containing at least one non-metal selected from the group consisting of S, Se, Te, and As, and v) one or more electron donors that provide donatable electrons to said anaerobic microbes during consumption of the electron donor by said anaerobic microbes; and (b) isolating said non-oxide semiconductor nanoparticles, which contain at least one of said metal ions and at least one of said non-metals.Type: ApplicationFiled: February 3, 2009Publication date: August 5, 2010Applicant: UT-BATTELLE, LLCInventors: Tommy J. Phelps, Robert J. Lauf, Ji Won Moon, Adam J. Rondinone, Lonnie J. Love, Chad Edward Duty, Andrew Stephen Madden, Yiliang Li, Ilia N. Ivanov, Claudia Jeanette Rawn